Brief: Clover Biopharmaceuticals Says Its Covid-19 Vaccine Candidate shows Superior Booster Responses
06/09/2022 24:04
Sept 6 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* CO'S COVID-19 VACCINE CANDIDATE DEMONSTRATES SUPERIOR
BOOSTER
RESPONSES COMPARED TO INACTIVATED VACCINE
* ANNOUNCE POSITIVE DATA FROM ONGOING PHASE 3 STUDY
EVALUATING
SCB- 2019 AS A UNIVERSAL COVID-19 BOOSTER VACCINE CANDIDATE
* FOCUSED ON COMPLETING REGULATORY SUBMISSIONS TO CHINA'S
NMPA,
EUROPEAN MEDICINES AGENCY, AND WHO FOR SCB-2019 IN H2 2022
Source text for Eikon: ID:
Further company coverage: 2197.HK
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune